• Теги
    • избранные теги
    • Компании177
      • Показать ещё
      Разное29
      • Показать ещё
      Страны / Регионы84
      • Показать ещё
      Международные организации4
      Показатели3
      Издания1
      Формат1
      Люди1
      Сферы1
Выбор редакции
23 марта, 13:16

Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?

Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

17 марта, 01:12

Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat

We issued an updated research report on Keryx Biopharmaceuticals, Inc. (KERX) on Mar 15, 2017.

08 марта, 17:45

Ionis Pharma Lipid Disorder Candidate Positive in Phase III

Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (IONS), recently announced positive results from a pivotal phase III study evaluating its pipeline candidate volanesorsen for treatment of patients with familial chylomicronemia syndrome.

24 февраля, 17:41

BioMarin (BMRN) Q4 Loss Narrower than Expected; Sales Beat

BioMarin Pharmaceutical Inc. (BMRN) reported a loss of 37 cents per share in the fourth quarter of 2016.

09 февраля, 19:07

Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise

Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.

09 февраля, 16:33

Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

07 февраля, 17:06

Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More

How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?

Выбор редакции
23 января, 14:32

Инновационный препарат для лечения рассеянного склероза становится более доступным

Препарат Lemtrada, выпускаемый фармацевтической компанией Sanofi Genzyme, был включен в государственную корзину медицинских услуг еще пару лет назад, но в 2017 году критерии его назначения стали более широкими.

11 января, 02:25

Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.

Выбор редакции
09 января, 16:11

Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

08 декабря 2016, 21:25

СМИ сообщили об эксперименте властей по возврату денег за неэффективное лечение

Фармкомпании могут получать деньги только за эффективные препараты. Об этом сообщает РБК со ссылкой на копию распоряжения вице-премьера Игоря Шувалова. Шувалов...

Выбор редакции
05 декабря 2016, 17:10

Alnylam Reports Positive Data on Fitusiran, Givosiran

Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

Выбор редакции
15 ноября 2016, 16:53

Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.

Alnylam Pharmaceuticals, Inc. (ALNY) announced that Genzyme, the specialty care global business unit of Sanofi (SNY), has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe.

Выбор редакции
Выбор редакции
03 ноября 2016, 15:45

Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up

Alnylam (ALNY) reported a loss of $1.21 per share in the third quarter of 2016 on revenues of $13.7 million.

31 октября 2016, 16:14

Sanofi (SNY) Beats Earnings, Revenues Rise Y/Y; Ups View

Sanofi (SNY) reported third-quarter 2016 business earnings of $1.00 per American Depositary Share, which beat the Zacks Consensus Estimate of 86 cents by 16.28%.

28 октября 2016, 17:21

BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus

BioMarin Pharmaceutical (BMRN) reported a loss of 18 cents per share in the third quarter of 2016, narrower than the year-ago loss of 44 cents.